期刊
CELLS
卷 10, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/cells10071679
关键词
autophagy flux; lung cancer; epidermal growth factor receptor (EGFR); 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3); cytoprotective autophagy
类别
资金
- Kentucky Lung Cancer Research Program [KL-CRP GB160444]
This study identifies PFKFB3 as a mediator of erlotinib-induced autophagy in NSCLCs and demonstrates that PFKFB3 inhibition sensitizes NSCLCs to erlotinib by impairing autophagy flux. The findings reveal a novel crosstalk between PFKFB3 and EGFR in regulating erlotinib-induced autophagy and contributing to erlotinib sensitivity in NSCLCs.
Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs). However, intrinsic or acquired resistance remains a clinical barrier to the success of FDA-approved EGFR TKIs. Multiple mechanisms of resistance have been identified, including the activation of prosurvival autophagy. We have previously shown that the expression and activity of PFKFB3-a known driver of glycolysis-is associated with resistance to erlotinib and that PFKFB3 inhibition improves the response of NSCLC cells to erlotinib. This study focuses on investigating the role of PFKFB3 in regulating erlotinib-driven autophagy to escape resistance to erlotinib. We evaluated the consequence of pharmacological inhibition of PFKFB3 on erlotinib-driven autophagy in NSCLC cells with different mutation statuses. Here, we identify PFKFB3 as a mediator of erlotinib-induced autophagy in NSCLCs. We demonstrate that PFKFB3 inhibition sensitizes NCSLCs to erlotinib via impairing autophagy flux. In summary, our studies uncovered a novel crosstalk between PFKFB3 and EGFR that regulates erlotinib-induced autophagy, thus contributing to erlotinib sensitivity in NSCLCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据